|
**Overview**: Diabetes Basic Panel**Introduction**: The Diabetes Basic Panel is a diagnostic tool designed to screen for diabetes using serum and plasma samples. In India, diabetes affects ~77 million adults (prevalence ~11 percent), with high rates of undiagnosed cases in rural/low-SES populations due to limited screening, leading to complications (nephropathy, retinopathy, CVD). Fasting glucose, HbA1c, random glucose are key for diagnosis and monitoring. High morbidity from delayed detection, limited access to glucometers/HbA1c testing, poor glycemic control. Per endocrinology practices aligned with ICMR and RSSDI guidelines, the test employs spectrophotometry for markers over 1-2 days with high accuracy, valuable for screening and diagnosis. This diagnostic falls under diabetes screening and targets individuals with risk factors (family history, obesity, sedentary lifestyle), addressing accurate detection to guide lifestyle modification, metformin, or insulin. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing complications. Its serum/plasma-based approach ensures reliable detection.**Other Names**: Diabetes Basic Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: HbA1c diagnostic standard; in India, key in NCD programs.**Purpose**: The test assesses 3 parameters including fasting glucose and HbA1c to guide diabetes screening, diagnose hyperglycemia, inform management.**Test Parameters**: 1. Fasting Glucose, 2. HbA1c, 3. Random Glucose.**Pretest Condition**: Fasting 10-12 hours required for fasting glucose; patients should report polyuria, thirst, weight loss.**Specimen**: 3 mL serum in 1 SST and plasma in NaF tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on symptoms, family history, obesity, hypertension.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated diabetes including complications, benefits of early detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent meals can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated glucose/HbA1c indicates diabetes/prediabetes, necessitating specialist input. Normal may require follow-up in high-risk.**Specialist Consultation**: Diabetologists should be consulted for management.**Additional Supporting Tests**: OGTT for confirmation.**Test Limitations**: HbA1c affected by hemoglobinopathies; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Diabetes Studies India 2023. |
